Amphastar Pharmaceuticals Inc (AMPH) Position Boosted by Rhumbline Advisers

Rhumbline Advisers increased its position in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 13.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,688 shares of the company’s stock after buying an additional 9,455 shares during the period. Rhumbline Advisers’ holdings in Amphastar Pharmaceuticals were worth $1,552,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its holdings in Amphastar Pharmaceuticals by 1.1% during the second quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock worth $512,000 after buying an additional 312 shares during the last quarter. Prudential Financial Inc. increased its holdings in Amphastar Pharmaceuticals by 8.3% during the third quarter. Prudential Financial Inc. now owns 63,580 shares of the company’s stock worth $1,136,000 after buying an additional 4,850 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its holdings in Amphastar Pharmaceuticals by 58.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock worth $239,000 after buying an additional 4,960 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its holdings in Amphastar Pharmaceuticals by 1.8% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 283,200 shares of the company’s stock worth $5,060,000 after buying an additional 5,000 shares during the last quarter. Finally, Swiss National Bank increased its holdings in Amphastar Pharmaceuticals by 11.8% during the fourth quarter. Swiss National Bank now owns 66,400 shares of the company’s stock worth $1,278,000 after buying an additional 7,000 shares during the last quarter. Institutional investors and hedge funds own 44.82% of the company’s stock.

How to Become a New Pot Stock Millionaire

Amphastar Pharmaceuticals stock opened at $18.61 on Friday. The company has a current ratio of 2.79, a quick ratio of 1.85 and a debt-to-equity ratio of 0.12. Amphastar Pharmaceuticals Inc has a 52-week low of $13.15 and a 52-week high of $20.45. The company has a market cap of $862.59, a price-to-earnings ratio of 60.03, a price-to-earnings-growth ratio of 1.52 and a beta of 1.46.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Monday, March 12th. The company reported $0.10 EPS for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.03. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.56%. The firm had revenue of $60.40 million during the quarter, compared to analysts’ expectations of $60.62 million. During the same period in the previous year, the business posted $0.01 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. equities analysts predict that Amphastar Pharmaceuticals Inc will post 0.63 EPS for the current year.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 19,801 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total transaction of $398,000.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason B. Shandell sold 18,627 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, January 26th. The stock was sold at an average price of $19.42, for a total transaction of $361,736.34. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 84,387 shares of company stock valued at $1,659,763. Company insiders own 11.10% of the company’s stock.

AMPH has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Piper Jaffray Companies restated a “buy” rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a report on Tuesday, January 30th. Finally, Needham & Company LLC boosted their target price on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $21.33.

WARNING: “Amphastar Pharmaceuticals Inc (AMPH) Position Boosted by Rhumbline Advisers” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3299374/amphastar-pharmaceuticals-inc-amph-position-boosted-by-rhumbline-advisers.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Canfor  Reaches New 12-Month High at $30.30
Canfor Reaches New 12-Month High at $30.30
Tekcapital  Reaches New 52-Week Low at $14.00
Tekcapital Reaches New 52-Week Low at $14.00
Safestore  Reaches New 1-Year High at $539.50
Safestore Reaches New 1-Year High at $539.50
Privatix  Price Hits $5.83 on Exchanges
Privatix Price Hits $5.83 on Exchanges
Comparing Continental Building  and USG
Comparing Continental Building and USG
Babcock & Wilcox  vs. Vivint Solar  Financial Contrast
Babcock & Wilcox vs. Vivint Solar Financial Contrast


© 2006-2018 Ticker Report. Google+.